The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced an expansion of its partnership with the Children's Tumor Foundation (CTF) to create unique neurofibromatosis (NF) pathway maps aimed at significantly increasing the understanding of the disease and its underlying mechanisms.
The Children's Tumor Foundation is using Thomson Reuters manually curated content and Life Sciences Professional Services to achieve its mission of finding a cure for neurofibromatosis. It utilizes Thomson Reuters Integrity to scout for new compounds; customized Disease Funding Schema to create a better understanding of how its funding impacts research; and Thomson Reuters MetaCore to support data visualization and enhance the understanding of NF through the development of disease-specific pathways.
The Children's Tumor Foundation has expanded its role as a research partner to academia and industry, alongside its funding focus. Thomson Reuters is helping this effort through the creation of a fully integrated systems biology capability. The collaboration includes the reconstruction and analysis of causal networks underlying NF mechanisms and the development of a comprehensive collection of NF1 & NF2 pathology pathway maps. These will be available to researchers through the CTF website via Thomson Reuters MetaCore, an integrated software suite for functional data analysis.
"Thomson Reuters content and services are essential to our Foundation being viewed as an active research partner with valuable systems biology insights," said Annette Bakker, president of the Children's Tumor Foundation. "Thomson Reuters is a trusted partner with the breadth of content and expertise needed to find new treatments and a cure for neurofibromatosis. The Thomson Reuters solutions we have, and how we apply them, are unique and game changing for our organization."
The Children's Tumor Foundation is a non-profit organization dedicated to the research and more effective treatment of neurofibromatosis, a genetic disorder that can cause tumors to grow on nerves throughout the body. One in every 3,000 people is afflicted with neurofibromatosis; most suffer from painful, non-cancerous growths that can result in blindness, hearing loss, physical deformities and learning disabilities.
"It is an honor to expand our partnership with the Children's Tumor Foundation in its search for a cure for neurofibromatosis," said Chris McKenna, general manager of discovery science, Thomson Reuters Life Sciences. "The maps we are helping them develop will provide NF researchers with a unique resource to reveal the mechanisms behind the disease and further accelerate the drug discovery process."
Standardized screening leads to earlier autism diagnoses in pediatric care